{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:41:18Z","timestamp":1762605678764,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011893","name":"PAHO","doi-asserted-by":"publisher","award":["SCON-2020-00286"],"award-info":[{"award-number":["SCON-2020-00286"]}],"id":[{"id":"10.13039\/100011893","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.vhri.2024.100998","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T19:27:28Z","timestamp":1715110048000},"page":"100998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews"],"prefix":"10.1016","volume":"43","author":[{"given":"Mar\u00edlia Berlofa","family":"Visacri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayra Carvalho","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis Satoshi","family":"Komoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno Kosa Lino","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Roberto Silveira","family":"Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1via de Oliveira Motta","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela Fernanda dos Santos","family":"Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.vhri.2024.100998_bib1","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2024.100998_bib2","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2021.07.028","article-title":"Management of myeloma Manifestations and Complications: the Cornerstone of Supportive Care: recommendation of the Canadian myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium","volume":"22","author":"LeBlanc","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.vhri.2024.100998_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.vhri.2024.100998_bib4","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.clml.2018.08.005","article-title":"Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American countries","volume":"19","author":"Pessoa de Magalh\u00e3es Filho","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.vhri.2024.100998_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.vhri.2024.100998_bib6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.4065\/79.7.899","article-title":"Thalidomide: tragic past and promising future","volume":"79","author":"Rajkumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.vhri.2024.100998_bib7","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/2040620711413165","article-title":"The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development","volume":"2","author":"Rehman","year":"2011","journal-title":"Ther Adv Hematol"},{"issue":"10","key":"10.1016\/j.vhri.2024.100998_bib8","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1590\/1413-812320182410.28522017","article-title":"The tale of lenalidomide clinical superiority over thalidomide and regulatory and cost-effectiveness issues","volume":"24","author":"Paumgartten","year":"2019","journal-title":"Cien Sa\u00fade Colet"},{"key":"10.1016\/j.vhri.2024.100998_bib9","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902020000318726","article-title":"Pharmacovigilance of thalidomide in the Brazilian Health System and patient safety","volume":"56","author":"Drummond","year":"2020","journal-title":"Braz J Pharm Sci"},{"issue":"6","key":"10.1016\/j.vhri.2024.100998_bib11","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x20165128","article-title":"Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and\/or thalidomide","volume":"49","author":"Castro","year":"2016","journal-title":"Braz J Med Biol Res"},{"issue":"18","key":"10.1016\/j.vhri.2024.100998_bib12","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.vhri.2024.100998_bib13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2174\/1568009617666170214104426","article-title":"Immunomodulatory drugs (IMiDs) in multiple myeloma","volume":"17","author":"Raza","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"10.1016\/j.vhri.2024.100998_bib14","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2020009752","article-title":"Persistent challenges with treating multiple myeloma early","volume":"137","author":"Goodman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.vhri.2024.100998_bib16","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.2","article-title":"Overviews of reviews","author":"Pollock","year":"2021"},{"key":"10.1016\/j.vhri.2024.100998_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-070849","article-title":"Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement","volume":"378","author":"Gates","year":"2022","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vhri.2024.100998_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.vhri.2024.100998_bib18","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vhri.2024.100998_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/10428194.2016.1177772","article-title":"A\u00a0systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation","volume":"58","author":"Weisel","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.vhri.2024.100998_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/OTT.S123680","article-title":"Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials","volume":"10","author":"Liu","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"11","key":"10.1016\/j.vhri.2024.100998_bib23","article-title":"Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis","volume":"2019","author":"Piechotta","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.vhri.2024.100998_bib24","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3324\/haematol.2018.206912","article-title":"Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis","volume":"104","author":"Blommestein","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.vhri.2024.100998_bib25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2019.07.001","article-title":"Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: a systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials","volume":"143","author":"Sekine","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.vhri.2024.100998_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/ejh.13407","article-title":"Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients","volume":"105","author":"Gil-Sierra","year":"2020","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.vhri.2024.100998_bib27","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/10428194.2019.1683736","article-title":"Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis","volume":"61","author":"Ramasamy","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.vhri.2024.100998_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103504","article-title":"Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: a network meta-analysis","volume":"168","author":"Kiss","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.vhri.2024.100998_bib29","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s12325-022-02083-8","article-title":"Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: a systematic literature review and network meta-analysis","volume":"39","author":"Facon","year":"2022","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.vhri.2024.100998_bib30","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/leu.2017.111","article-title":"Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial","volume":"31","author":"Bahlis","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.vhri.2024.100998_bib31","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.vhri.2024.100998_bib32","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.vhri.2024.100998_bib33","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3324\/haematol.2019.222299","article-title":"Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study","volume":"105","author":"Nielsen","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.vhri.2024.100998_bib34","first-page":"1451","article-title":"Steps towards a multiple myeloma cure?","volume":"12","author":"Gozzetti","year":"2022","journal-title":"J\u00a0Pers Med"},{"issue":"4","key":"10.1016\/j.vhri.2024.100998_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2021.151173","article-title":"Multidisciplinary professional roles addressing needs in multiple myeloma: an innovative \u2018virtual\u2019 pharmacist surveillance clinic","volume":"37","author":"Ebied","year":"2021","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.vhri.2024.100998_bib36","first-page":"37","article-title":"Managing treatment-related peripheral neuropathy in patients with multiple myeloma","volume":"6","author":"Grammatico","year":"2016","journal-title":"Blood Lymphat Cancer"},{"issue":"9","key":"10.1016\/j.vhri.2024.100998_bib37","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1159\/000365534","article-title":"Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy","volume":"37","author":"Koeppen","year":"2014","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.vhri.2024.100998_bib38","article-title":"Chemotherapy-induced peripheral neuropathy impacts quality of life and activities of daily living of Brazilian multiple myeloma patients","author":"de Miranda Drummond","year":"2023","journal-title":"Curr Drug Saf"},{"issue":"9","key":"10.1016\/j.vhri.2024.100998_bib44","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40273-021-01050-5","article-title":"Implementing outcomes-based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel","volume":"39","author":"Facey","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"Supl.1","key":"10.1016\/j.vhri.2024.100998_bib45","first-page":"101","article-title":"Risk Sharing Agreement: a pilot project in the Brazilian Unified Health System","volume":"14","author":"Vianna","year":"2022","journal-title":"J\u00a0Bras Econ Sa\u00fade"},{"issue":"2","key":"10.1016\/j.vhri.2024.100998_bib46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/2157930X.2019.1567964","article-title":"The potential synergies between industrial and health policies for access to medicines: insights from the Brazilian policy of universal access to HIV\/AIDS treatment","volume":"9","author":"Urias","year":"2019","journal-title":"Innov Dev"},{"key":"10.1016\/j.vhri.2024.100998_bib47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.critrevonc.2017.03.014","article-title":"Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses","volume":"113","author":"Aguiar","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"131","key":"10.1016\/j.vhri.2024.100998_bib48","first-page":"1","article-title":"Systematic review adherence to methodological or reporting quality","volume":"6","author":"Pussegoda","year":"2017","journal-title":"Syst Rev"},{"issue":"1","key":"10.1016\/j.vhri.2024.100998_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"11","key":"10.1016\/j.vhri.2024.100998_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081823","article-title":"Publication bias in recent meta-analyses","volume":"8","author":"Kicinski","year":"2013","journal-title":"PLoS One"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:33:20Z","timestamp":1762605200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109924000311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":42,"alternative-id":["S2212109924000311"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.100998","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.100998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100998"}}